RenalGuard Therapy
DeviceRenalGuard Therapy
NCT Number: NCT06811805
The goal of this clinical trial is to assess the effect of RenalGuard Therapy in reducing the rates of Acute Kidney Injury (AKI) within 72 hours after cardiac surgery in patients at risk of developing Cardiac Surgery Associated AKI (CSA-AKI) compared to standard-of-care (SoC).
Participants will be randomized (1:1) to one of the two study groups. The Treatment study group will be managed with the RenalGuard System. The RenalGuard treatment will start after induction of anesthesiology and will run during surgery and for 6-7 hours in the Intensive Care Unit (ICU). The treatment will aim to achieve a urine rate above a predefined urine rate threshold. Patients in the control group will be managed based on the usual clinical practice in cardiac surgery centres as detailed in the recommendations for CSA-AKI prevention by accepted clinical guidelines.
For both study groups general anaesthesia, cardiopulmonary bypass (CPB) run and overall patient care will be based on SoC for cardiac surgery.
Patients will be followed up for up to 7 days post surgery or until discharge, which ever comes first.
Long-term follow up will be performed at 90 days post surgery.
This study is active but is not currently recruiting participants.
Notify Me18 year and older
All sexes
Interventional
Not applicable
Jessa Medica Center, Hasselt, Belgium
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
RenalGuard Therapy
Standard of care
Time frame: Within 72 hours
CSA-AKI is defined as when any of the following three criteria are met:
Time frame: Within 72 hours
Time frame: Within 72 hours
CSA-AKI severity by stage distribution between the study groups
Time frame: Within 7 days
AKI incidence within 7 days based on the KDIGO definition described in the primary endpoint section
Time frame: Within 7 days
Duration of AKI within 7 days of surgery
Time frame: 90 days post-surgery
MAKE-90 will be defined as:
Time frame: 7 days
Time frame: 7 days
CardioRenal Systems, Inc.
Industry
Post-Marketing Clinical Follow Up Study to Further Assess the Safety & Efficacy of RenalGuard® Therapy in the Prevention of Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI)
Acronym: KIDNEY-II
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06705855
AKI - Acute Kidney Injury, Acute Kidney Injury
Salt Lake City, Utah, United States
View Trial DetailsNCT07123935
AKI - Acute Kidney Injury, Acute Kidney Injury
Kuala Lumpur, Malaysia
View Trial DetailsNCT06596785
AKI - Acute Kidney Injury, Acute Kidney Injury
Jinan, Shandong, China
View Trial DetailsNCT07722325
AKI - Acute Kidney Injury, Acute Kidney Injury
View Trial Details